$63.480
0.000 (0.00%)Al cierre
- High
- 63.480
- Open
- 63.480
- VWAP
- —
- Vol
- 0.00
- Mkt Cap
- 10.21B
- Low
- 63.480
- Amount
- 0.00
- EV/EBITDA, TTM
- 16.42
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
Analyst Ratings (11)
Baird
$64
2024-09-24
Baird
2024-09-24
Precio objetivo
$64
William Blair
—
2024-09-03
William Blair
2024-09-03
Precio objetivo
—
RBC Capital
$64
2024-07-11
RBC Capital
2024-07-11
Precio objetivo
$64
Barclays
$63
2024-06-28
Barclays
2024-06-28
Precio objetivo
$63
Stephens & Co.
$64
2024-04-04
Stephens & Co.
2024-04-04
Precio objetivo
$64
Métricas de valoración
Cronología de eventos
Noticias
9.008-25BenzingaFDA Raises Concerns Over Serious Contamination Issues at Novo Nordisk Indiana Facility, Including Cat Hair, Bacteria, and Foreign Objects
9.504-02Investing.comNovo Holdings nearly doubles earnings as Wegovy swells coffers By Reuters
8.501-16Investing.comNovo Holdings looks to double Catalent size with eye on Trump US manufacturing focus By Reuters
8.512-18NewsfilterLennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
8.512-18PRnewswireLennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
CTLT FAQ — answered by Alphio AI
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
11 analysts cover CTLT: 7 rate it Buy, 4 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.